Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

18.47USD
20 Apr 2018
Change (% chg)

$-0.39 (-2.07%)
Prev Close
$18.86
Open
$18.77
Day's High
$18.80
Day's Low
$18.21
Volume
245,302
Avg. Vol
496,449
52-wk High
$23.50
52-wk Low
$5.47

Latest Key Developments (Source: Significant Developments)

Spectrum Pharma Q4 Loss Per Share $0.29
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Spectrum Pharmaceuticals Inc ::SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS AND PIPELINE UPDATE.Q4 NON-GAAP LOSS PER SHARE $0.23.Q4 LOSS PER SHARE $0.29.SEES FY 2018 REVENUE $90 MILLION TO $110 MILLION.Q4 REVENUE $28.6 MILLION.  Full Article

Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update.Q3 non-GAAP loss per share $0.11.Q3 loss per share $0.22.Q3 revenue $36.4 million.  Full Article

Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2.  Full Article

Spectrum Pharma Q2 non-gaap loss per share $0.05
Tuesday, 9 Aug 2016 

Spectrum Pharmaceuticals Inc : Q2 loss per share $0.35 . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S . Spectrum pharmaceuticals reports second quarter 2016 financial results and pipeline update . Q2 non-gaap loss per share $0.05 .Q2 revenue $33.9 million versus i/b/e/s view $30.9 million.  Full Article

Spectrum says unit Allos Therapeutics and Fresenius Kabi USA reach settlement to resolve patent litigation
Wednesday, 13 Jul 2016 

Spectrum Pharmaceuticals Inc : Spectrum says unit Allos Therapeutics and Fresenius Kabi USA entered into settlement agreement to resolve patent litigation relating to Folotyn . Details of settlement are confidential, parties will submit agreement to Federal Trade Commission and Department of Justice . Says Fresenius will be permitted to market a generic version of Folotyn In United States On November 15, 2022- Sec filing . Says parties will request that court enter an order, in which it will dismiss company's litigation against Fresenius .Says Fresenius was last remaining defendant in litigation, which accordingly is expected to conclude.  Full Article

Spectrum Pharmaceuticals' unit, Allos Therapeutics and Sandoz enter settlement agreement
Thursday, 9 Jun 2016 

Spectrum Pharmaceuticals Inc : On June 8, 2016, co's unit , Allos Therapeutics and Sandoz Inc entered into a settlement agreement . Spectrum Pharmaceuticals Inc says settlement agreement to resolve patent litigation relating to folotyn . Sandoz will be permitted to market generic version of folotyn in U.S on November 15, 2022 or earlier under certain circumstances . Details of settlement confidential, parties will submit agreement to ftc and department of justice . Spectrum Pharmaceuticals says parties will request that court enter an order, in which it will dismiss company's litigation against sandoz .Spectrum Pharmaceuticals Inc says company's litigation against one other generic filer continues.  Full Article

Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier
Tuesday, 31 May 2016 

Spectrum Pharmaceuticals : Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn .dr. Reddy's will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain circumstances.  Full Article

Spectrum Pharma says unit, Teva enter settlement agreement
Wednesday, 25 May 2016 

Spectrum Pharmaceuticals Inc : Unit, teva pharmaceuticals usa, inc. Entered into settlement agreement to resolve patent litigation relating to Folotyn . Teva will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain terms . Details of settlement are confidential, and parties will submit agreement to federal trade commission and doj .Parties will request that court enter an order, in which it will dismiss company's litigation against teva.  Full Article

US STOCKS-Wall St hits session highs as trade war worries fade

* Indexes up: Dow 2.05 pct, S&P 1.68 pct, Nasdaq 1.73 pct (Adds quote, updates prices)